RESEARCH TRIANGLE PARK, NC--(Marketwire - June 11, 2009) - Pharmaceutical business
intelligence firm Cutting Edge Information announces the launch of its
latest therapeutic area study, which provides forecasts for the autoimmune
market.
"Autoimmune Market Forecast to 2014"
(
http://www.cuttingedgeinfo.com/autoimmune-forecast/) analyzes key trends
currently affecting the autoimmune disease landscape and their impact on
drug development and sales through 2014. Although scientists have
classified more than 100 different autoimmune disorders, most research
revolves around six indications: rheumatoid arthritis, lupus, Crohn's
disease, ulcerative colitis, psoriasis, and multiple sclerosis. The report
details the historical, current, and forecasted performance of more than 40
drugs -- marketed brands and pipeline products -- and the top nine
manufacturers within these indications.
"One blockbuster sustaining a company is a scenario occurring less
frequently, but the era of the blockbuster drug has not ended," says
Shaylyn Pike, the report's lead author. "The autoimmune market presents
amazing opportunities for companies looking to replace dying revenue
streams. Of the 43 brands we profiled, 14 will become blockbusters before
2014 -- more than half of which will top $3 billion in annual sales."
"Autoimmune Market Forecast to 2014" presents breakdowns of individual
drugs and classes. Besides providing in-depth market analysis for each
product, it compares data across brands, classes and company portfolios --
leading to an honest and accurate evaluation of performance: advantages,
potential pitfalls, competitive threats, and clinical successes and
failures.
The report examines the following drug classes:
-- TNF inhibitors
-- B-cell inhibitors
-- Interferon betas
-- Interleukin inhibitors
-- Immunomodulators
-- NSAIDs
-- 5-ASAs
-- Antimetabolites
-- Corticosteroids
-- JAK inhibitors
The report is organized into indication snapshots, brand profiles and drug
manufacturer profiles:
Indication snapshots provide an overview of each of the six main autoimmune
indications and their associated complications. Analysis includes a look
at the indication's history, pathology, epidemiology and treatment
regimens.
Brand Profiles detail a product's competitive and strategic positioning,
market opportunities, and patent and litigation data. Profiles include:
-- Drug's current and projected competitive strength
-- Sales projection charts through 2014
-- Materiality charts
-- Clinical trial information
-- Patent/market exclusivity tables
Company Profiles show breakdowns for the nine companies with the
highest-grossing autoimmune portfolios. Profiles contain:
-- Ranking within market
-- Strengths analysis
-- Growth areas analysis
-- Key products breakdown
Download a complimentary report brochure at
http://www.cuttingedgeinfo.com/autoimmune-forecast/?download
Contact Information: CONTACT:
Shaylyn Pike
919-433-0385